Zimmer Biomet’s hips, sports medicine and technology businesses grew while knees declined in the third quarter of 2026, according to the company’s Nov. 4 earnings release.
Here are seven things to know from the report:
- Net sales rose 3.1% to $2.06 billion in the third quarter of 2026. U.S. sales rose 3.6% to $1.21 billion, and international sales rose 2.4% to $857.2 million.
- Knee sales fell 3.1% to $767.5 million, with U.S. knee sales falling 2.0% to $431.3 million, while international knee sales decreased 4.5% to $336.3 million.
- Hip sales rose 6.0% to $536.5 million. U.S. hip sales rose 5.8% to $280.1 million, and international hip sales rose 6.2% to $256.4 million.
- The company’s S.E.T. category rose 6.8% to $578.3 million, which covers sports medicine, biologics, foot and ankle, upper extremities, trauma, craniomaxillofacial and thoracic products.
- Technology & Data, Bone Cement and Surgical sales grew fastest, rising 11.9% to $180.6 million. Separately, the company extended a multiyear limited exclusive distribution and supply agreement with THINK Surgical, a robotics company.
- CEO Ivan Tornos said hips, S.E.T. and Technology & Data, Bone Cement and Surgical, which he said represent two-thirds of the company’s business, grew at upper-single-digit or double-digit rates. He said the results validate “the progress of our diversification strategy.”
- Through the first nine months of 2026, the company’s net sales rose 5.7% to $6.33 billion.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
